NCT02464319View on ClinicalTrials.gov

A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

June 1, 2015

Primary Completion Date

March 31, 2017

Study Completion Date

August 31, 2017

Conditions
Primary Sjögren's Syndrome
Interventions
DRUG

hrIL-2 active

1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1

DRUG

hrIL-2 placebo

1 million U doses of placebo s.c. injection active group: placebo group =1:1

Trial Locations (1)

100044

Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing

All Listed Sponsors
collaborator

Monash University

OTHER

collaborator

Beijing ShuangLu Pharmaceutical Co., Ltd.

OTHER

lead

Peking University People's Hospital

OTHER

NCT02464319 - A Phase II Study With Low-dose Recombinant Human IL-2 for the Treatment of Primary Sjögren's Syndrome | Biotech Hunter | Biotech Hunter